Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hypofractionated RT Clear all
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery

NCT03324802
View directory record Official record
Conditions
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 24, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

NCT04601831
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Focal radiation therapy (RT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

NCT06110572
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Interventions
Carboplatin, Atezolizumab, Etoposide, Total Body Irradiation, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging
Drug · Biological · Radiation + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting Phase 1 Interventional

Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

NCT06812052
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
Radiation Therapy, Hypofractionationed Radiation Therapy
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

NCT05406232
View directory record Official record
Conditions
Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

NCT04454528
View directory record Official record
Conditions
Breast Cancer
Interventions
Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Not yet recruiting Phase 1 Interventional

Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac

NCT07457307
View directory record Official record
Conditions
High-grade Glioma
Interventions
MR-Linac System, Radiation Therapy, Temozolomide
Device · Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

NCT04068194
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Peposertib
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
46
States / cities
Duarte, California • Irvine, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional

Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy

NCT02307058
View directory record Official record
Conditions
Prostate Cancer
Interventions
LEAD RT, HEIGHT RT
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT03796767
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis, Prostate Adenocarcinoma, PSA Failure
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Completed Not applicable Interventional Results available

Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer

NCT01278212
View directory record Official record
Conditions
Breast Cancer
Interventions
accelerated hypofractionated radiotherapy (AHF-RT)
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
21 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 1 Interventional

Ultra-fractionated Radiotherapy for Rectal Cancer

NCT04677413
View directory record Official record
Conditions
Rectal Cancer
Interventions
Ultrafractionated radiotherapy for rectal cancer
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

NCT06529809
View directory record Official record
Conditions
Locally Advanced Cervical Carcinoma
Interventions
Hypofractionated external beam radiation, Chemotherapy, Image-guided brachytherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT04221893
View directory record Official record
Conditions
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

NCT04486755
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 3 Interventional

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

NCT03367702
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
276
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial

NCT05077735
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Hypofractionated Radiation Therapy, Questionnaire Administration, Magnetic Resonance Imaging, Computed Tomography Scan
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
12
States / cities
Gilbert, Arizona • San Diego, California • Greeley, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Completed Early Phase 1 Interventional

UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

NCT03224871
View directory record Official record
Conditions
METASTATIC NON-SMALL CELL LUNG CANCER
Interventions
Intralesional IL-2, Nivolumab, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 24, 2026, 1:56 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

NCT04748419
View directory record Official record
Conditions
Lung Cancer, Carcinoma, Non-Small Cell Lung
Interventions
consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Terminated Not applicable Interventional Results available

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

NCT02672033
View directory record Official record
Conditions
Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 3 Interventional

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

NCT01223248
View directory record Official record
Conditions
Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
Interventions
IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 24, 2026, 1:56 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NCT05603910
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy
Drug · Radiation
Lead sponsor
Aaron Wolfson
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02179086
View directory record Official record
Conditions
Glioblastoma
Interventions
Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
230
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 1:56 AM EDT